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Bendamustine is an intravenously-administered alkylating
agent approved as monotherapy or in combination with other
agents for the treatment of refractory hematologic malignancies,
such as chronic lymphocytic leukemia (CLL) and B-cell non-
Hodgkin lymphoma.1,2 Despite bendamustine is well-tolerated, it
can provoke allergic reactions as well as drug fever.3,4 To our knowl-
edge, there are not reported cases of immunological reactions with
an allergological study carried out.
We present three patients diagnosed with B-cell CLL (B-CLL)
treated with bendamustine as monotherapy suffered from hyper-
sensitivity reactions. Patient 1: A 61-year-old woman, diagnosed
with B-CLL received bendamustine, tolerating the ﬁrst cycle. Three
weeks later, 8 h after the 1st dose of the 2nd cycle, she suffered
throat discomfort, pruritus, hives, general erythema and facial
swelling; which disappeared within 24 h after treatment. Patient
2: A 61-year-old man, diagnosed with B-CLL. Four years ago, he
adequately tolerated bendamustine. One week later after the 1st
and well tolerated cycle, he received the 2nd one and 8e10 h after
the dose he developed a maculopapular exanthema, edema in arms
and legs, along with desquamation of hands and feet, without re-
sidual lesions. Symptoms disappeared within the ﬁrst 2 weeks. Pa-
tient 3: A 63-year-old man, diagnosed with B-CLL. Three hours after
the infusion of the 1st and 2nd cycles of bendamustine, he had
generalized tremor and fever of 39 C. The symptoms ceased with
acetaminophen 650 mg. One month later, 3 h after the 3rd cycle
of bendamustine, he had generalized tremor and erythema, dizzi-
ness and body temperature of 39 C. Hypotension, paroxysmal
atrial ﬁbrillation and a mild renal failure were veriﬁed. The symp-
toms disappeared with acetaminophen 1gr and an adequate
hydration.
We performed skin-prick-test (SPT) at 1 mg/ml and intradermal
testing (IDT) at 0.001, 0.01, 0.1 and 1 mg/ml, with immediate (at
20 min), late (before 12 h), and delayed (at 24 h and 72 h) readings.
As negative controls three B-CLL patients underwent SPT and IDT
with negative results. These different concentrations did not pro-
voke neither cutaneous necrosis nor hyperpigmentation. Patient 1.
SPT was negative. IDT at 0.1 and 1 mg/ml were positive at 24 h, be-
ing negative 72 h later (Fig.1). Of note, although the positivity of the
IDT was detected at 24 h, the maximum expression of intensity was
produced at home between 6 and 10 h (late response) after ﬁnish-
ing skin tests in our outpatient clinic. The rest of the tests were
negative. Patient 2. He had a negative SPT. The 24 h readings ofPeer review under responsibility of Japanese Society of Allergology.
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72 h later (Fig. 2). The rest of the tests were negative. Patient 3.
The SPT and IDT (immediate and delayed readings) were negative.
In this work, we report the ﬁrst two cases of reactions to bend-
amustine with a positive result for the IDT in the allergological
study carried out, which demonstrated a hypersensitivity to bend-
amustine. We also report the ﬁrst case of drug fever induced by
bendamustine in clinical use, where the work-up carried out did
not demonstrated neither a type I nor a IV hypersensitivity mech-
anism to this drug.
Clinically, the cutaneous reactions expressed on the patientss1
ands2 are justiﬁed by different mechanisms. In fact, patient s 1
suffered from a typical IgE-mediated reaction (Type I hypersensitiv-
ity reaction) revealed by means of a positive IDT in its late reading
(another kind of immediate reading). Nevertheless, patients2 suf-
fered from a typical maculopapular exanthema with an associated
edema on arms and legs revealed by means of a positive IDT in its
delayed reading to three different concentrations, remaining posi-
tive 72 h later. In this case, we think that this cutaneous reaction
could be produced by Th2 cells with/without eosinophils and/or
IL-4, IL-5, IL-13 secretion (Type IVb hypersensitivity reaction), often
associated with an IgE-mediated type I reaction, which would
justify the associated edema. Other possibility would be a direct
T-cell stimulation by means of perforin/granzyme B from cytotoxic
lymphocytes (Type IVc hypersensitivity reaction).5
Drug fever is a common condition that is frequently misdiag-
nosed, being a diagnosis of exclusion.6 A febrile response that coin-
cides temporally with the administration of a drug, disappears after
discontinuation of the offending agent, and reappears after a new
administration, constitutes the unique diagnostic criterion.7 In
nonsensitized individuals receiving a drug for the ﬁrst time, the
onset of fever is highly variable.
There are different mechanisms provoking fever induced by
drugs in oncologic patients: neutropenic fever (or febrile neutrope-
nia), infectious fever, tumor fever, blood transfusion fever, and drug
fever (early or later).8 In drug fever, a stimulation of cytokines (IL-6,
TNF-a), as well as immune complex aggregation are involved.5 The
use of antineoplasic chemotherapy or the neoplasia itself may pro-
voke drug fever by neoantigens production. In any case, this would
be attributed to a type IIa hypersensitivity reaction, where comple-
ment proteins or IgG/IgM antibodies are implicated.9 It is also
possible that drug fever may be due to a systemic reaction by im-
mune complex, complement activation and/or neutrophil recruit-
ment, that is, a type IIIb hypersensitivity reaction, being involved
either complement or antigen and IgG.9 The patient s3 did not
exhibit any feature of vasculitis, glomerulonephritis, peripheralevier B.V. All rights reserved.
Fig. 1. Lectures of the intradermal tests with bendamustine at 24 h: negative at 0.001
and 0.01, and positive at 0.1 and 1 mg/ml.
Fig. 2. Lectures of the intradermal tests with bendamustine at 24 h: negative at 0.001
and positive at 0.01, 0.1 and 1 mg/ml.
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hypocomplementemia or abnormal liver function tests, as it can
appear in serum sickness and systemic erythematosus lupus.7
Furthermore,we suspect that a type IIa hypersensitivitymechanismshould justify the cases of drug fever happened after the ﬁrst doses
of the drug in the life of the subject, due to the involvement of IgM
instead of IgG, as it may occurred to our patient (a nonsensitized in-
dividual). Unfortunately, due to a lack of facilities, anti-
bendamustine IgG or IgM antibodies and/or a validated basophil
activation test could not be tested and so, this proposedmechanism
could not be established conclusively.
On the other hand, some cases of bendamustine-induced fever
have been described, all of them in clinical trials (phases I to III), us-
ing different high doses of this drug, ranging from 80 to 100mg/m2,
and with a variable incidence of 3e40% of cases.3,4,10 The
patient s3 suffered from fever after doses of 70 mg/m2 in three
consecutive occasions. To accomplish this treatment regimen, he
needed a pretreatment with dexamethasone 16 mg just previously
the perfusion plus ranitidine and aspirine from 24 h before it,
showing no new reaction.
To the best of our knowledge, we present the ﬁrst three-case
report of reactions by bendamustine wherein an allergological
workup has been performed. Two patients suffered from immedi-
ate and delayed cutaneous hypersensitivity reactions, respectively,
and the other one from a bendamustine-induced fever. Further
studies are needed in order to clarify the true immunopathogenesis
in these reactions, particularly in the latter entity.Acknowledgments
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